Open AccessThis article is
- freely available
Obesity Drug Update: The Lost Decade?
Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI 48201, USA
* Author to whom correspondence should be addressed.
Received: 5 October 2010; in revised form: 17 November 2010 / Accepted: 23 November 2010 / Published: 24 November 2010
Abstract: The growing worldwide obesity epidemic and obesity-related disorders present a huge unmet medical need for safe and effective anti-obesity medications. The discovery of leptin in 1994 was rapidly succeeded by a wave of related discoveries leading to the elaboration of a hypothalamic melanocortinergic neuronal circuit regulated by leptin and other central and peripheral signaling molecules to control energy homeostasis. The identification of specific neuronal subtypes along with their unique connections and expression products generated a rich target menu for anti-obesity drug discovery programs. Over the course of the last decade, several new chemical entities aimed at these targets have reached various stages or successfully completed the drug discovery/regulatory process only to be dropped or taken off the market. There are now in fact fewer options for anti-obesity drug therapies in late 2010 than were available in 2000. The challenge to discover safe and effective anti-obesity drugs is alive and well.
Keywords: obesity; anti-obesity drug targets; anti-obesity drugs; hypothalamus
Citations to this Article
Cite This Article
MDPI and ACS Style
Yao, F.; MacKenzie, R.G. Obesity Drug Update: The Lost Decade? Pharmaceuticals 2010, 3, 3494-3521.
Yao F, MacKenzie RG. Obesity Drug Update: The Lost Decade? Pharmaceuticals. 2010; 3(12):3494-3521.
Yao, Fayi; MacKenzie, Robert George. 2010. "Obesity Drug Update: The Lost Decade?" Pharmaceuticals 3, no. 12: 3494-3521.